|Mr. Robert W. Azelby M.B.A.||Pres, CEO & Director||678k||N/A||1968|
|Ms. Erin M. Lavelle||Exec. VP, COO & CFO||502.88k||N/A||1978|
|Ms. Valerie Morisset Ph.D.||Chief Scientific Officer and Exec. VP of R&D||497.15k||N/A||1970|
|Mr. James B. Bucher J.D.||Exec. VP & Gen. Counsel||N/A||N/A||1966|
|Ms. Amy Chappell M.D.||Chief Medical Officer||N/A||N/A||N/A|
|Ms. Jo Palmer-Phillips Ph.D.||Chief Devel. Officer||N/A||N/A||N/A|
|Julio E. Vega||Sec.||N/A||N/A||N/A|
Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in disorders of the peripheral and central nervous systems. Its two lead drug candidates are ETX-810 for chronic pain and ETX-155 for major depressive disorder, perimenopausal depression, and focal onset seizures. The company also develops preclinical pipeline programs, such as Kv7 Program for pain epilepsy; and Anxiolytic for the treatment of generalized anxiety. Eliem Therapeutics, Inc. was incorporated in 2018 and is headquartered in Redmond, Washington.
Eliem Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.